On December 18, 2025, Core Scientific, Inc. (CORZ) garnered a **Market Outperform** rating from Greg Miller at Citizens, underscoring the company’s strong potential as its current share price of $13.57 matches up with a price target of $30. This positive shift in analyst sentiment signals greater confidence in Core Scientific’s growth trajectory, which may appeal to investors looking for promising opportunities in a volatile sector.
Recent Price Action
In recent trading sessions, CORZ has displayed notable volatility, indicative of broader investor sentiment towards risk assets. Closing at **$13.57**, the stock witnessed a **6.45% increase** or **$0.88** within the trading day. This price movement comes against the backdrop of a **market cap of approximately $4.48 billion**, alongside a beta of **6.78**, suggesting it is significantly more volatile than the overall market. The range of CORZ’s stock over the past year has been stark, with a 52-week high of **$118.87** and a low of **$42.57**, reflecting the heightened speculative nature of cryptocurrency-related investments. Despite these dramatic fluctuations, the recent volume of **6,288,525** shares traded was relatively lower than the **average volume of 15,624,232**, indicating that while interest remains, it may not be at peak levels currently.
[chart type=’price’ value=’CORZ’]
Short- and Long-Term Performance
Over the past 30 days, Core Scientific has faced challenges, down **8.25%** as broader market conditions pressured tech and cryptocurrency stocks. The quarterly performance did not fare better, registering a decline of **18.99%**, while the yearly perspective remains down **12.68%**. Volatility measures are sobering, with weekly volatility at **7.28%** and monthly volatility at **7.26%**, suggesting that investors can expect substantial price swings as the market continues to react to shifting sentiments in crypto and tech sectors. Averaging **13,113,882** in volume over the last ten days, and **15,682,560** over three months, this declining performance reflects a cautious market, possibly influenced by economic fears and shifting investor priorities.
[chart type=’performance’ value=’CORZ’]
Earnings / Financials
A recent earnings report reveals a less-than-ideal EPS (earnings per share) situation for Core Scientific. The reported EPS was **-$0.46**, significantly lower than the estimated EPS of **-$0.0698**, leading to a surprise factor of **558.93%**. This stark discrepancy harkens back to the previous report, which posted an actual EPS of **-$0.04** against an estimate of **-$0.07**, revealing a negative surprise of **42.86%**. The pronounced miss in expected earnings presents concerns regarding Core Scientific’s profitability efficiency in the current economic landscape.
[chart type=’income-bar-chart’ value=’CORZ’]
Analyst / Consensus View
In light of recent earnings and stock performance, the consensus among analysts appears to lean favorably towards CORZ. The most recent ratings suggest that out of **9 total ratings**, **8** are classified as **Buys**, with only **1** hold and no sells, reinforcing a predominantly bullish outlook. The average price target based on these ratings is approximately **$25.39**, with a high forecast of **$34** and a low of **$18**. Such consensus underscores a belief among analysts that despite the current headwinds, the company possesses upward potential, aligning with the recent Market Outperform upgrade.
[chart type=’analyst-ratings’ value=’CORZ’]
Stock Grading or Fundamental View
Core Scientific currently boasts a **Stocks Telegraph Grade** of **52**, which indicates moderate strength in its investment profile. This score is derived from a comprehensive analysis of financial health, competitive stance, and market dynamics, suggesting that while the company shows some promising fundamentals, there are substantial risks and uncertainty within its operational framework and industry sector.
[chart type=’st-cards’ value=’CORZ’]
Conclusion
For investors, Core Scientific, Inc. (CORZ) represents a compelling opportunity, especially for those inclined towards growth and high-risk sectors. Its recent rating upgrade and analyst confidence resonate positively in a shaky marketplace. However, the significant volatility and recent earnings misses warrant careful consideration. A cautious approach, assessing both high reward potential and inherent risks, would be prudent. Long-term growth investors, in particular, may find value here, although they should remain vigilant of overall market trends and company-specific developments before diving in. Given the current climate, monitoring updates surrounding Core Scientific will be essential for making informed investment decisions.